File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia

TitleThe Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia
Authors
KeywordsProteasome inhibitors
Acute lymphoblastic leukaemia
Bortezomib
Carfilzomib
Ixazomib
Issue Date2021
PublisherFrontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/oncology
Citation
Frontiers in Oncology, 2021, v. 11, article no. 802832 How to Cite?
AbstractAcute lymphoblastic leukaemia (ALL) is an aggressive haematolymphoid malignancy. The prognosis of ALL is excellent in paediatric population, however the outcome of relapse/refractory disease is dismal. Adult ALL has less favourable prognosis and relapse/refractory disease is not uncommonly encountered. Bortezomib is the first generation proteasome inhibitor licensed to treat plasma cell myeloma and mantle cell lymphoma with favourable side effect profile. Efficacy of bortezomib had been proven in other solid tumors. Clinical studies showed promising response for proteasome inhibitors in treating relapse/refractory ALL. Thus, proteasome inhibitors are attractive alternative agents for research in treating ALL. In the review article, we will introduce different proteasome inhibitors and their difference in pharmacological properties. Moreover, the mechanism of action of proteasome inhibitors on ALL will be highlighted. Finally, results of various clinical studies on proteasome inhibitors in both paediatric and adult ALL will be discussed. This review article provides the insights on the use of proteasome inhibitors in treating ALL with a summary of mechanism of action in ALL which facilitates future research on its use to improve the outcome of ALL.
Persistent Identifierhttp://hdl.handle.net/10722/309127
ISSN
2023 Impact Factor: 3.5
2023 SCImago Journal Rankings: 1.066
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorSin, CF-
dc.contributor.authorMan, PHM-
dc.date.accessioned2021-12-14T01:40:55Z-
dc.date.available2021-12-14T01:40:55Z-
dc.date.issued2021-
dc.identifier.citationFrontiers in Oncology, 2021, v. 11, article no. 802832-
dc.identifier.issn2234-943X-
dc.identifier.urihttp://hdl.handle.net/10722/309127-
dc.description.abstractAcute lymphoblastic leukaemia (ALL) is an aggressive haematolymphoid malignancy. The prognosis of ALL is excellent in paediatric population, however the outcome of relapse/refractory disease is dismal. Adult ALL has less favourable prognosis and relapse/refractory disease is not uncommonly encountered. Bortezomib is the first generation proteasome inhibitor licensed to treat plasma cell myeloma and mantle cell lymphoma with favourable side effect profile. Efficacy of bortezomib had been proven in other solid tumors. Clinical studies showed promising response for proteasome inhibitors in treating relapse/refractory ALL. Thus, proteasome inhibitors are attractive alternative agents for research in treating ALL. In the review article, we will introduce different proteasome inhibitors and their difference in pharmacological properties. Moreover, the mechanism of action of proteasome inhibitors on ALL will be highlighted. Finally, results of various clinical studies on proteasome inhibitors in both paediatric and adult ALL will be discussed. This review article provides the insights on the use of proteasome inhibitors in treating ALL with a summary of mechanism of action in ALL which facilitates future research on its use to improve the outcome of ALL.-
dc.languageeng-
dc.publisherFrontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/oncology-
dc.relation.ispartofFrontiers in Oncology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectProteasome inhibitors-
dc.subjectAcute lymphoblastic leukaemia-
dc.subjectBortezomib-
dc.subjectCarfilzomib-
dc.subjectIxazomib-
dc.titleThe Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia-
dc.typeArticle-
dc.identifier.emailSin, CF: scf185@hku.hk-
dc.identifier.authoritySin, CF=rp02290-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3389/fonc.2021.802832-
dc.identifier.scopuseid_2-s2.0-85122306604-
dc.identifier.hkuros330986-
dc.identifier.volume11-
dc.identifier.spagearticle no. 802832-
dc.identifier.epagearticle no. 802832-
dc.identifier.isiWOS:000745235400001-
dc.publisher.placeSwitzerland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats